Keros Therapeutics Q2 EPS $(1.27) Beats $(1.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
Keros Therapeutics reported Q2 losses of $(1.27) per share, beating the analyst consensus estimate of $(1.34) by 5.22 percent. However, this represents a 12.39 percent increase in losses compared to the same period last year.
August 07, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Keros Therapeutics reported better than expected Q2 losses, but the losses increased compared to last year.
While Keros Therapeutics beat the analyst consensus estimate for Q2 losses, the fact that losses increased compared to the same period last year could have a neutral impact on the stock. Investors may be encouraged by the beat, but concerned about the increased losses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100